Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress
April 09 2015 - 10:12AM
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) today announced that it
was recognized with a prestigious industry award at the World
Vaccine Congress being held this week in Washington, D.C. The
Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine
advancements and achievements of therapeutic and preventive vaccine
developers across the worldwide industry as judged by a panel of
global biotech industry stakeholders.
Inovio was given accolades by its industry peers for "Best
Therapeutic Vaccine" for its DNA-based immunotherapy, VGX-3100,
which was designed to treat HPV-associated precancers and cancers.
In a large, controlled phase II efficacy trial Inovio reported top
line data demonstrating regression of disease and clearance of the
underlying cause of the condition – the HPV virus. Inovio expects
to publish the complete data set in a peer-reviewed journal this
year, is advancing this product into a phase III trial early next
year, and has expanded studies of this immunotherapy to include
cervical and head and neck cancer.
Each year, the award recognizes the therapeutic vaccine that
addresses an unmet medical need and holds significant potential for
vast geographical and market reach. This is the third consecutive
year that Inovio's lead product has won this designation.
Also selected for recognition by the World Vaccine Congress as
the "Best Academic Research Team" was the lab headed by Dr. David
B. Weiner, Chair of Inovio's Scientific Advisory Board and
Professor of Pathology and Laboratory Medicine at The Perelman
School of Medicine at the University of Pennsylvania. This award,
given annually to the research group that has produced products
with a novel mode of action, seen them progress into human trials,
and can demonstrate significant supportive research grants, was
given to Dr. Weiner and his lab for making significant
contributions to the field of DNA vaccines.
Dr. J. Joseph Kim, President and CEO, said, "There is a clear
unmet need for a non-surgical option for women with cervical
precancers around the world. We greatly appreciate the World
Vaccine Congress' recognition of Inovio's VGX-3100 potential to
address this opportunity.
"I'm also pleased to see my mentor and collaborator, Dave
Weiner, recognized for his body of work out of which the field of
DNA vaccines emerged. His lab continues to introduce not only an
array of new products but is also advancing important new
technology innovations.
"These two awards highlight the focused research and clinical
development that are the foundation of Inovio's intellectual
property and commercial goals. With a core technology consisting of
proprietary DNA-based plasmids and electroporation delivery, we now
have multiple approaches to optimize the immune system's inherent
capabilities to fight cancers and infectious diseases."
About the ViE Awards
The World Vaccine Congress & Expo, now in its 15th year, is
the largest and most comprehensive event in the industry. Covering
everything from the latest R&D to manufacturing to corporate
development strategies, the Congress hosts the only awards ceremony
dedicated to the vaccine industry. The ViE Awards honor
individuals, organizations and initiatives which have made
significant contributions over the past 12 months to innovation in
the field of vaccines.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
MedImmune, University of Pennsylvania, DARPA, Drexel University,
NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and University of Manitoba. For more
information, visit www.inovio.com.
This press release contains certain forward-looking statements
relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon® active immune
therapy and vaccine products, our ability to advance our portfolio
of immune-oncology products independently, including INO-5150, and
to commence a phase I clinical trial for INO-5150 in the first half
of 2015, the adequacy of our capital resources, the availability or
potential availability of alternative therapies or treatments for
the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the company and
its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development
programs, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2014,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals,
858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals,
267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024